PJI is devastating to patient health, frustrating to surgeons, and costly to healthcare systems. It represents a lifetime risk for any patient that has had joint replacement surgery and can occur in any replaced joint such as knees, hips, shoulders, etc.
The current Standard of Care (SOC) for treatment is suboptimal. Multiple studies document high failure rates resulting in repeated surgeries and extended patient morbidity. Current treatment failure is primarily due to persistent bacterial BIOFILM, which is not eradicated by low concentration of antibiotics in the joint This is a limitation of using current SOC administration.